Last Updated : March 21, 2025
Canada’s Drug Agency Announces a New Round of Funding to Enhance Rare Disease Registries
Canada’s Drug Agency has launched a new funding opportunity for rare disease registries to enhance their capability and implement improvement initiatives, to support decision-making in Canada related to drugs for rare diseases. This marks our second funding opportunity for rare disease registries, following the successful launch of last year’s inaugural open call for funding.
New Watch List Spotlights Advances and Issues in Artificial Intelligence Use in Canadian Health Care
The use of artificial intelligence (AI) has the potential to reshape many aspects of the health care systems in Canada, from streamlining documentation and workflows to improving how conditions are diagnosed and tailoring treatments plans.
The 2025 Watch List, published by Canada’s Drug Agency, signals 5 AI technologies that are poised to have a meaningful impact on health systems. The report helps unpack the hype from the hope about these technologies and also identifies 5 key issues that will significantly influence their wider adoption and implementation.
Details
CT services are essential for diagnosing various conditions in Canada. There are existing challenges with access to these services due to the limited availability of machines, high demand for services, and long wait times. Rural and remote communities may experience additional challenges, as these services are often located in large urban centres.
Health Economics Methods Advisory Group Selects First Area for Study: Assessing Treatment Benefits Appropriate to Consider in HTA Decision-Making
The US-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have selected the first research topic for the Health Economics Methods Advisory (HEMA) group: an assessment of the benefits of treatment that are appropriate to consider in health technology assessment (HTA) de
Canada’s Drug Agency Named One of the National Capital Region’s Top Employers
Today, for the 2nd year running Canada’s Drug Agency was named one of the National Capital Region's top employers for 2025.
Canada’s Drug Agency Seeks Nominations for Expert and Advisory Committee Members
Canada’s Drug Agency is seeking knowledgeable and experienced individuals to join our expert and advisory committees.
Our annual call for nominations is now open for the following positions: